These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 9187933)

  • 1. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease.
    Arai H; Higuchi S; Sasaki H
    Gerontology; 1997; 43 Suppl 1():2-10. PubMed ID: 9187933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.
    Lasser RA; Dukoff R; Levy J; Levin R; Lehtimäki T; Seubert P; Sunderland T
    Int J Geriatr Psychiatry; 1998 Nov; 13(11):767-74. PubMed ID: 9850873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up.
    Blomberg M; Jensen M; Basun H; Lannfelt L; Wahlund LO
    Neurosci Lett; 1996 Aug; 214(2-3):163-6. PubMed ID: 8878109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects.
    Engelborghs S; Dermaut B; Goeman J; Saerens J; Mariën P; Pickut BA; Van den Broeck M; Serneels S; Cruts M; Van Broeckhoven C; De Deyn PP
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1148-51. PubMed ID: 12876259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease.
    Arai H; Terajima M; Miura M; Higuchi S; Muramatsu T; Matsushita S; Machida N; Nakagawa T; Lee VM; Trojanowski JQ; Sasaki H
    J Am Geriatr Soc; 1997 Oct; 45(10):1228-31. PubMed ID: 9329486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Significance for etiological theories of Alzheimer's disease.
    Harrington CR; Louwagie J; Rossau R; Vanmechelen E; Perry RH; Perry EK; Xuereb JH; Roth M; Wischik CM
    Am J Pathol; 1994 Dec; 145(6):1472-84. PubMed ID: 7992850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study.
    Andreasen N; Vanmechelen E; Van de Voorde A; Davidsson P; Hesse C; Tarvonen S; Räihä I; Sourander L; Winblad B; Blennow K
    J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):298-305. PubMed ID: 9527138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity.
    Ganzer S; Arlt S; Schoder V; Buhmann C; Mandelkow EM; Finckh U; Beisiegel U; Naber D; Müller-Thomsen T
    J Neural Transm (Vienna); 2003 Oct; 110(10):1149-60. PubMed ID: 14523627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease.
    Tapiola T; Lehtovirta M; Ramberg J; Helisalmi S; Linnaranta K; Riekkinen P; Soininen H
    Neurology; 1998 Jan; 50(1):169-74. PubMed ID: 9443475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease.
    Fukuyama R; Mizuno T; Mori S; Yanagisawa K; Nakajima K; Fushiki S
    Eur Neurol; 2000; 43(3):161-9. PubMed ID: 10765057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease].
    Schonknecht P; Pantel J; Werle E; Hartmann T; Essig M; Baudendistel K; Beyreuther K; Schroder J
    Fortschr Neurol Psychiatr; 2000 Oct; 68(10):439-46. PubMed ID: 11103680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia.
    Martinoli MG; Trojanowski JQ; Schmidt ML; Arnold SE; Fujiwara TM; Lee VM; Hurtig H; Julien JP; Clark C
    Acta Neuropathol; 1995; 90(3):239-43. PubMed ID: 8525796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.
    Arai H; Terajima M; Miura M; Higuchi S; Muramatsu T; Machida N; Seiki H; Takase S; Clark CM; Lee VM
    Ann Neurol; 1995 Oct; 38(4):649-52. PubMed ID: 7574462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele.
    Skoog I; Vanmechelen E; Andreasson LA; Palmertz B; Davidsson P; Hesse C; Blennow K
    Neurodegeneration; 1995 Dec; 4(4):433-42. PubMed ID: 8846237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease.
    Golombowski S; Müller-Spahn F; Romig H; Mendla K; Hock C
    Neurosci Lett; 1997 Apr; 225(3):213-5. PubMed ID: 9147408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.